Skip to main content
. 2017 Aug 18;13:1043–1051. doi: 10.2147/TCRM.S142348

Table 2.

Association of immunosuppressant utilization with NODALT

Immunosuppressant Recipients without NODALT (n=1,951) Recipients with NODALT (n=189) p-value
Cyclosporine (CsA) 363 (18.61%) 36 (19.05%) 0.8816
Tacrolimus (TAC) 1,691 (86.67%) 181 (95.77%) 0.0003*
Mycophenolate mofetil (MMF) 1,472 (75.45%) 156 (82.54%) 0.0291*
Sirolimus 376 (19.27%) 40 (21.16%) 0.5303
Everolimus 165 (8.46%) 13 (6.88%) 0.4529

Notes: Immunosuppressant utilization was defined as the presence of drug code in more than 10% of the total immunosuppressant prescriptions. Tacrolimus and mycophenolate mofetil had significant correlations with the incidence of NODALT;

*

p<0.05.

Abbreviation: NODALT, new-onset diabetes after liver transplantation.